Montigny Le Tilleul

Researchers are evaluating a new approach to radiotherapy for patients with glioblastoma, a common and aggressive brain tumor. This trial aims to determine if focusing radiation treatment more precisely by reducing the usual safety margin can safely decrease side effects and improve quality of life. Despite current treatments involving surgery, radiotherapy, and chemotherapy, survival remains limited and quality of life is often impaired for these patients. The study compares two radiotherapy approaches one with the standard irradiation volume including a 15mm safety margin around the tumor, and another with a reduced 10mm margin to limit the amount of healthy brain tissue exposed. Both groups receive chemoradiotherapy as part of their treatment. This national multicenter trial will randomize patients to either the standard or reduced radiotherapy volume to assess outcomes. Participants will be followed for up to two years with regular assessments of overall survival, neurocognitive function, treatment-related toxicity, quality of life, disease progression, and recurrence patterns. Evaluations include baseline measurements and follow-ups at one month and one year after radiotherapy. Researchers will also monitor use of anti-edema therapy during the study. The total participation duration and study procedures are designed to monitor safety and the impact of the radiation volume on patient well-being.